Akero Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -262.63 M

Akero Therapeutics, Inc. Operating Cash Flow is USD -262.63 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 68.49% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Akero Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -155.88 M, a 65.34% change year over year.
  • Akero Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -94.27 M, a 11.95% change year over year.
  • Akero Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -84.21 M, a 8.19% change year over year.
  • Akero Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -77.83 M.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities